The market has been high on Nektar Therapeutics (NKTR) stock recently. NKTR gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With NKTR Stock Today?
Nektar Therapeutics (NKTR) stock has risen 1.71% while the S&P 500 is down -0.29% as of 2:32 PM on Tuesday, Jul 7. NKTR has gained $0.41 from the previous closing price of $23.98 on volume of 365,470 shares. Over the past year the S&P 500 has risen 6.54% while NKTR is down -28.64%. NKTR lost -$2.62 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Nektar Therapeutics click here.
More About Nektar Therapeutics
Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.
